Marschall et al. [17] recently reported that the therapeutic effects of IFN-α on neuroendocrine tumor cells were based on Sp1- and/or Sp3-mediated inhibition of VEGF transcription both in vivo and in vitro. The gene discussed is IFNA1; the disease is neuroendocrine neoplasm.